Hi-Lab
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hi-Lab - overview
Established
2022
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Based in Beijing, China and founded in 2022, Hi‑Lab (Beijing) Biotechnology Co. , Ltd. , dba Hi‑Lab, focuses on advancing the discovery and development of First‑in‑Class and Best‑in‑Class antibody drug candidates. The company engages in domestic and international pipeline collaborations to support global biopharmaceutical innovation.
The company conducts research and development of multi-specific and bispecific antibody therapeutics with applications in cancer, autoimmune, and metabolic disease treatment. Its services include biologic design, preclinical evaluation, and partnership‑driven clinical development support. The company generates revenue from research collaborations, licensing of its therapeutic technologies, and development partnerships with biopharmaceutical organizations. In December 2025, Hi-Lab closed nearly CNY 60 million in Angel funding led by YuanBio Venture, with participation from new investors Tsinghua Innovation Ventures, Beishang Capital, Flyfot Ventures and Zero2IPO Ventures.
Current Investors
Zero2IPO Ventures, YuanBio Venture, Tsinghua Innovation Ventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.